



#4

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 99,898-A)

In the Application of:

Guolin Cai et al.

Serial No. 09/864,846

Filed: May 24, 2001

For: Oxo-Imidazopyridine-Carboxamides

RECEIVED

OCT 17 2001

TECH CENTER 1600/2900

Examiner: not assigned

Art Unit: 1645

INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.98 the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the references cited below are enclosed. These references are also listed on the enclosed PTO Form 1449.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

1. WO 01/16103, published March 8, 2001.
2. WO 97/34870, published September 25, 1997.
3. WO 97/26243, published July 24, 1997.
4. WO 98/02420, published January 22, 1998.
5. WO 99/18105, published April 15, 1999.

Serial No. 09/864,846
Filed: May 24, 2001
Group Art Unit: 1645

6. EP 0 050 563 A, published April 28, 1982.
7. WO 99/37303, published July 29, 1999.
8. WO 99/47131, published September 23, 1999.
9. WO 99/47142, published September 23, 1999.
10. WO 99/47171, published September 23, 1999.
11. Giuseppe, Trapani et al., "Synthesis and Binding Affinity of 2-Phenylimidazo '1,2!pyridine Derivatives for both Central and Peripheral Benzodiazepine Receptors. A New Series of High-Afinity and selective Ligands for the Peripheral Type", *J. Medicinal Chemistry*, Vol. 40, no. 19, 1997, pages 3109-3118.
12. Barnard, E.A. et al., "International Union of Pharmacology. XV. Subtypes of gamma-Aminobutyric AcidA Receptors: Classification on the Basis of Subunit Structure and Receptor Function:, *Pharmacological Reviews*, vol. 50, no. 2, 1998, pages 291-313.

Also, enclosed is a copy of the European Search Report in which the above-listed references were cited during the prosecution of a corresponding PCT application.

In accordance with MPEP Sections 609 and 707.05(b), it is requested the document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that


Serial No. 09/864,846
Filed: May 24, 2001
Group Art Unit: 1645


the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

Respectfully submitted,
McDONNELL BOEHNEN
HULBERT & BERGHOF
300 South Wacker Drive
Chicago, Illinois 60606
(312) 913-0001

Date: October 11, 2001

By:


Steven J. Sarussi
Reg. No. 32,784



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 99,898-A)

1645

In the Application of:

Guolin Cai et al.

Serial No. 09/864,846

Filed: May 24, 2001

For: Oxo-Imidazopyridine-Carboxamides

Examiner: not assigned

Art Unit: 1645

Commissioner for Patents
Washington, D.C. 20231

Sir:

TRANSMITTAL LETTER

RECEIVED

OCT 17 2001

TECH CENTER 1600/2900

In regard to the above identified application:

1. We are transmitting herewith the attached:

- a. Information Disclosure Statement
- b. PTO Form-1449 with 12 cited references;
- c. Copy International Search Report, and
- d. Postcard.

2. With respect to additional fees:

X A. No fees are necessary at this time

B. Charge the total additional fee to our Deposit Account No. 13-2490.
A duplicate copy of this sheet is enclosed.

3. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490.
A duplicate copy of this sheet is enclosed.

4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this 11th day of October 2001.

By: 

Steven J. Sarussi
Reg. No. 32,784

McDONNELL BOEHNEN
HULBERT & BERGHOFF
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001